Welcome to our dedicated page for Tyra Biosciences news (Ticker: TYRA), a resource for investors and traders seeking the latest updates and insights on Tyra Biosciences stock.
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company based in Carlsbad, California that focuses on developing next-generation precision medicines targeting FGFR biology. The news flow around TYRA, as reflected in its recent press releases, centers on clinical trial progress, scientific presentations, regulatory designations and corporate developments related to its FGFR-focused pipeline.
Investors and followers of TYRA news can expect updates on dabogratinib (formerly TYRA-300), the company’s lead oral FGFR3-selective inhibitor. Recent announcements include dosing the first patient in the SURF302 Phase 2 study for FGFR3-altered intermediate risk non-muscle invasive bladder cancer, dosing the first child in the BEACH301 Phase 2 study for pediatric achondroplasia, and plans to expand development into low-grade upper tract urothelial carcinoma through the SURF303 study. Tyra also reports interim proof-of-concept results in metastatic urothelial carcinoma and regulatory designations such as Orphan Drug Designation and Rare Pediatric Disease Designation for dabogratinib in achondroplasia.
News coverage further highlights progress in early-stage oncology programs TYRA-200 and TYRA-430, including enrollment and dosing in the SURF201 and SURF431 Phase 1 studies for intrahepatic cholangiocarcinoma, hepatocellular carcinoma and other FGFR-driven tumors. Tyra’s communications also describe scientific visibility events, such as a late-breaking poster on TYRA-300 preclinical data at ENDO 2025 and fireside chats or presentations at healthcare and biotechnology investor conferences.
In addition, Tyra Biosciences issues quarterly financial results press releases and Form 8-K filings that summarize research and development spending, cash runway expectations and key clinical milestones. Corporate news has included strengthening the leadership team with appointments in operations and regulatory affairs. For readers tracking TYRA, this news stream provides ongoing insight into the company’s clinical development timelines, scientific activities and corporate priorities in FGFR-targeted precision medicine.
Tyra Biosciences (TYRA) reported its Q1 2022 financial results, highlighting a net loss of $14.8 million, up from $4.2 million in Q1 2021. Operating expenses rose significantly with research and development costs reaching $9.6 million and general administrative expenses at $5.2 million. The company has cash and equivalents of $292.5 million as of March 31, 2022, reassuring investors of its financial stability. Tyra plans to file INDs for its lead product candidates, TYRA-300 and TYRA-200, by mid-2022 and the second half of 2022, respectively.
Tyra Biosciences (Nasdaq: TYRA) reported its fourth quarter and full year 2021 financial results, highlighting a net loss of $9.9 million for Q4 and $26.3 million for the year, compared to $3.7 million and $9.3 million, respectively, in 2020. R&D expenses surged to $7.2 million in Q4 from $2.9 million a year prior, while total cash reached $302.2 million. Anticipated FDA IND submissions for TYRA-300 and TYRA-200 are planned for 2022, alongside a strengthening of the clinical team.
Tyra Biosciences (Nasdaq: TYRA) announced its participation in the Cowen 42nd Annual Healthcare Conference from March 7-9, 2022. CEO Todd Harris will be featured in a panel on March 8, 2022, at 9:10 am ET. The event aims to highlight the company's focus on precision oncology and its proprietary SNÅP platform to develop therapies targeting tumor resistance. Investors can access a live webcast on the company's website. Tyra specializes in inhibitors for the Fibroblast Growth Factor Receptor (FGFR) family, crucial in treating various cancers.
Tyra Biosciences (Nasdaq: TYRA) will participate in the 2021 Jefferies London Healthcare Conference on November 18-19, 2021. Management will host a fireside chat and one-on-one investor meetings, with the chat available on-demand from November 18. The company focuses on developing precision oncology therapies to combat tumor resistance, featuring their proprietary SNÅP platform. Their lead product, TYRA-300, targets bladder cancer, while TYRA-200 aims at intrahepatic cholangiocarcinoma.
Tyra Biosciences, Inc. (Nasdaq: TYRA) announced its financial results for the quarter ending September 30, 2021. The company completed a $198.7 million IPO and strengthened its leadership team with key appointments. Cash and cash equivalents reached $312.8 million, expected to fund operations through at least 2024. R&D expenses rose to $5.5 million, while net loss for the quarter was $6.6 million, or $(0.72) per share. TYRA nominated TYRA-200 for clinical development, targeting FGFR2 mutations.
Tyra Biosciences, Inc. (Nasdaq: TYRA) has priced its upsized initial public offering of 10,800,000 shares at $16.00 per share, aiming to raise gross proceeds of $172.8 million. The shares are set to trade on the Nasdaq Global Select Market starting September 15, 2021, with the offering expected to close on September 17, 2021. A 30-day option has been granted to underwriters for an additional 1,620,000 shares. Tyra specializes in precision oncology and is focused on therapies targeting tumor resistance, particularly through its lead product candidate, TYRA-300, for bladder cancer.